Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017
18 July 2017 - 6:05AM
Business Wire
- Conference Call and Webcast to Follow at
5:00 p.m. EDT/ 2:00 p.m. PDT -
Exelixis, Inc. (NASDAQ:EXEL) announced today that its second
quarter 2017 financial results will be released on Wednesday,
August 2, 2017 after the markets close. At 5:00 p.m. EDT / 2:00
p.m. PDT, Exelixis management will host a conference call to
discuss the results and provide a general business update. The
conference call will be accessible via the Internet from the
company’s website.
To access the webcast link, log onto www.exelixis.com and
proceed to the Event Calendar page under Investors & Media.
Please connect to the company’s website at least 15 minutes prior
to the conference call to ensure adequate time for any software
download that may be required to listen to the webcast.
Alternatively, please call (855) 793-2457 (domestic) or (631)
485-4921 (international) and provide the conference call passcode
49002905 to join by phone.
A telephone replay will be available until 8:00 p.m. EDT on
August 4, 2017. Access numbers for the telephone replay are:
855-859-2056 (domestic) and 404-537-3406 (international); the
passcode is 49002905. A webcast replay will also be archived on
www.exelixis.com for one year.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company
committed to the discovery, development and commercialization of
new medicines to improve care and outcomes for people with cancer.
Since its founding in 1994, three products discovered at Exelixis
have progressed through clinical development, received regulatory
approval, and entered the marketplace. Two are derived from
cabozantinib, an inhibitor of multiple tyrosine kinases including
MET, AXL and VEGF receptors: CABOMETYX™ tablets approved for
previously treated advanced kidney cancer and COMETRIQ® capsules
approved for progressive, metastatic medullary thyroid cancer. The
third product, COTELLIC®, is a formulation of cobimetinib, a
reversible inhibitor of MEK, is marketed under a collaboration with
Genentech (a member of the Roche Group), and is approved as part of
a combination regimen to treat advanced melanoma. Both cabozantinib
and cobimetinib have shown potential in a variety of forms of
cancer and are the subjects of broad clinical development programs.
For more information on Exelixis, please visit www.exelixis.com or
follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, COMETRIQ and
COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S.
trademark.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170717006063/en/
Exelixis, Inc.Susan Hubbard, 650-837-8194Executive Vice
President, Public Affairs & Investor
Relationsshubbard@exelixis.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2024 to May 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From May 2023 to May 2024